HIGH EFFICIENCY MAMMALIAN GENE EXPRESSION VECTORS THAT CONTAIN EXOGENOUS PROMOTER AND ENTIRE 5' UNTRANSLATED REGION IN THE UPSTREAM FROM START CODON FOR INHERENT GENE AS TRANSCRIPTION REGULATORY SITE

Abstract: The present invention relates to the highly efficient eukaryotic expression vectors which have regulatory sequences derived from human cytomegalovirus immediate early gene or human EF1 alpha gene, thereof transcriptional regulatory regions contain exogenous promoter and entire 5' untranslated region correspond to the condition of inherent gene expression. Therefore, the eukaryotic expression vectors provided in accordance with the present invention can drive high levels of gene expression in human and animal cells and have utilities as gene therapy agent.

Description: HIGH EFFICIENCY MAMMALIAN GENE EXPRESSION VECTORS THAT CONTAIN EXOGENOUS PROMOTER AND ENTIRE 5' UNTRANSLATED REGION IN THE UPSTREAM FROM START CODON FOR INHERENT GENE AS TRANSCRIPTION REGULATORY SITE FIELD OF THE INVENTION To express foreign genes temporarily or permanently in eukaryotic cells, recombinant expression vectors should contain the promoter region, polyadenylation signal region and eukaryotic selectable marker gene as well as genes for replication and selection in E . col i . BACKGROUND Among the strategies for constructing recombinant vectors which can drive strong and stable expression of the gene of interest in animal cells, the representative method is to increase the level of gene expression by selecting efficient promoter or to induce self-replication of plasmid with SV40 replication origin by expressing SV40 T antigen. Recently, HCMV IE (human cytomegalovirus immediate early) promoter and human housekeeping gene EF1 a promoter have been exploited to drive higl levels of gene expression in eukaryotic cells. In addition, it has been reported that plasmid containing intron and untranslated exon sequences induce higher levels of gene expression than plasmid lacks intron sequences, so recombinant vectors with exogenous intron have been developed and used for stable and permanent gene expression. Since the development of vectors which can induce strong and stable gene expression in eukaryotic cells is very important for success in gene therapy trials and efficient foreign gene expression in animal cells, novel mammalian gene expression vectors which can induce strong and stable gene expression in permanent or temporal manner are required. Thus, the present inventors constructed eukaryotic gene expression vectors for stable and strong expression of foreign gene, based on the notices that vectors which have exogenous promoter and 5' untranslated region (5' UTR) containing entire exon and intron sequences in upstream from initiation codon for inherent gene induce efficient gene expression. Particularly, the vectors of the present invention are more efficient than HCMV IE or EFl a expression vector without exon or intron in vivo. In addition, chimeric vector which contain enhancer of HCMV IE gene upstream of EFl a promoter and its 5' UTR regiong can induce high levels of gene expression. SUMMARY OF THF, INVENTION It is an object of this invention to provide mammalian gene expression vector containing exogenous regulatory element for driving strong and stable gene expression m temporarily or permanently transfected various mammalian cells or m vivo. It is a further object of this invention to provide stable mammalian gene expression vector for gene therapy using naked DNA. It is an additional object of this invention to provide recombinant microorganism transformed with the said mammalian gene expression vector. In accordance with the present invention, the foregoing objects and advantages are readily obtained. The present invention provides eukaryotic expression vector which contains multi-clonmg site, polyadenylation signal region of bovine growth hormone, SV40 promoter and replication origin, marker gene and ColEI replication origin. The vector contains additionally regulatory elements for gene expression, exogenous promoter, and entire 5' untranslated region (hereinafter referred to as 5' UTR) m upstream of initiation codon of inherent translation. Particularly, this invention provides eukaryotic expression vector, which contains promoter/enhancer, exon 1, intron A and nucleotide sequences just before initiation codon ATG of exon 2 derived from HCMV IE as regulation element. In one preferred embodiment, this invention provides pCN vector comprising the regulatory element described by SEQ ID NO: 3. The present invention also provides eukaryotic expression vector, which contains promoter/enhancer, exon 1, intron A and nucleotide sequences just before initiation codon ATG of exon 2 derived from human EFl a gene as regulatory element. In one preferred embodiment, this invention provides pEF vector comprising the regulatory element described by SEQ ID NO: 6. This invention also provides chimeric vector pCEF, which is constructed by inserting enhancer of HCMV IE into upstream of EFl a promoter of pEF vector. This invention also provides minimized eukaryotic vector pCK, which is depleted unnecessary sequences and whose π-lactamase gene is replaced with kanamycme resistance gene. In addition, this invention provides vectors with useful foreign gene in multi-cloning site of pCN, pEF, pCK and pCEF. In one preferred embodiment, this invention provides pCN-VEGF, pEF-VEGF, pCK-VEGF and pCEF-VEGF comprising VEGF (vascular endothelial growth factor) gene. However, it should not be taken to limit the scope of the invention. In another aspect, this invention provides the E . coli strains transformed with the said vectors. In further aspect, this invention provides gene therapy agents containing the said vectors active ingredient. Further features of the present invention will appear hereinafter. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flow diagram for the construction of plasmid pCN by inserting the fragment encompassing enhancer/promoter and 5' UTR derived from HCMV IE gene into pCDNA3.1 FIG. 2 is a flow diagram for the construction of plasmid pEF by inserting the fragment encompassing enhancer/promoter and 5' UTR derived from human EFl a gene into pCDNA3.1 FIG. 3 is a flow diagram for the construction of pCEF by inserting the enhancer fragment derived from HCMV IE gene into pEFs vector containing promoter and partial intron sequence derived from EFl gene FIG. 4 is a flow diagram for the construction of pCK vector, FIG. 5 is a flow diagram for the construction of plasmid pCN/VEGF vector with VEGF121, FIG. 6a to 6b is a flow diagram for the construction of plasmids pCK/VEGF165, FIG. 7 is a flow diagram for the construction of pCP vector in which 5' UTR is deleted from pCK vector, FIG. 8 is a flow diagram for the construction of plasmids pCDNA3.1, and pCN . FIG. 9a to 9b is a flow diagram for the construction of plasmids pCP-gagrepresent the procedure for construction of pCP-gag/pol vector expressing gag- pol gene of MLV. FIG. 10a to 10b is a flow diagram for the construction of plasmid pCH-env expressing env gene of MLV, FIG. 11 is a histogram showing the gene expression levels of pCDNA3.1-VEGF, pEF-VEGF, pCN-VEGF and pCEF- VEGF vectors m transient transfection system, FIG. 12 is a flow diagram of the construction plasmid pEF-CAT, FIG. 13 is a histogram showing the CAT activities of HeLa cells transiently transfected pEF-CAT or pCN- CAT, FIG. 14 is a histogram showing the CAT activities of HeLa cells stably transfected with pEF-CAT or pCN- CAT, FIG. 15 is a histogram showing the time course of gene expression level of HeLa cells stably transfected with pEF-CAT or pCN-CAT vectors, FIG. 16 is a histogram showing the gene expression level of the subclones obtained from HeLa cell populations stably trandsfected with pEF-CAT or pCN-CAT vectors, FIG. 17 is a histogram showing the expression level of VEGF m the mouse muscle injected with pCN- VEGF vector, FIG. 18a to 18b is a flow diagram of the construction of plasmids pCK-CAT and pCN-CAT, FIG. 19 is a histogram showing CAT activities of C C cells transfected with pCK-VEGF or pCP-VEGF vector, FIG. 20 is a histogram showing VEGF levels of C C cells transfected with pCK-VEGF165 or pCP-VEGF165 vector, FIG. 21 is a histogram showing CAT activities of mouse muscle cells injected with pCK-CAT or pCP-CAT vector, FIG. 22 is a histogram showing VEGF levels of mouse muscle cell injected with pCK-VEGF or pCP-VEGF vector, FIG. 23 is a histogram showing the time course of gene expression in mouse muscle cells injected CAT gene, FIG. 24 is a histogram showing the time course of VEGF expression in mouse muscle cells injected with pCK-VEGF165 vector, FIG. 25 is a histogram showing dose-dependency of gene expression m mouse muscle injected with pCK-CAT, FIG. 26 is a histogram showing dose-dependency of gene expression in mouse muscle injected with pCK- VEGF165. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS Hereinafter, this invention is described in two cases of using HCMV IE promoter and using human EFl promoter . 1. Expression vector derived from HCMV IE gene 1) construction of pCN It has been reported that intron A sequence derived from the HCMV IE gene increases the level of gene expression (Chapman et al . , Nucl . Acids Res . , 19:3979-3986, 1991). Based on this report, the present inventors constructed the eukaryotic expression vector, pCN vector, which contains promoter/enhancer and 5' UTR, namely from the start site of RNA transcription to nucleotide sequences just before initiation codon ATG (exon 1, intron A and partial exon 2) derived from HCMV IE gene as regulatory element and wherein foreign gene is expressed from spliced RNA. The present inventors constructed more efficient eukaryotic gene expression vector using pCDNA3.1 ( Invitrogen) as initiation vector. DNA fragment containing enhancer/promoter and 5' UTR of HCMV IE gene was amplified by polymerase chain reaction ( PCR) , using pEQ276 vector (Biegalke et al., Virology, 183:381- 385(1995)) as a template. The amplified DNA fragment was replaced with the HCMV enhancer/promoter fragment of the pCDNA3.1 vector, for construction of pCN vector. The backbone of pCN is therefore identical to pCDNA3.1, but the foreign gene inserted into the multi-clonmg site is expressed from the spliced messenger RNA. 2) gene expression level from pCN In order to investigate the effect of HCMV IE 5' UTR on the level of gene expression, plasmids pCDNA3.1-CAT, pCN-CAT, and pCIneo-CAT were constructed by inserting the CAT reporter gene into pCDNA3.1, pCN , and pCIneo vector, respectively. 293T cells (DuBridge et al . , Mol . Cell . Biol . , 7:379-387, 1987) were transfected with these vectors, and the levels of CAT activity was measured in transfected cells. The CAT activity of cells transfected with pCN- CAT containing 5' UTR of HCMV IE, was about 60 times higher than that of cells transfected with vectors lacking 5'UTR. In addition, as another indicator to confirm the gene expression level, packaging efficiency was measured. Particularly, gag-pol and env genes derived from MLV were inserted into the pCN vector respectively, and the resulting vectors together with retroviral vector MFG-CAT(Kιm et al . , J. Virol., 72:994-1004,1998) were transfected to 293T cells. 2 days after the viral supernatant was used to transduce NIH 3T3 cells. As a result, the CAT activity was higher than other conventional packaging vectors were used, suggesting pckaging constructs based on pCN provided gag/pol and env proteins efficiently. These results indicate that pCN vector of the present invention is very efficient expression vector. 2. Construction of expression vector derived from human EFlα gene 1) construction of plasmid pEF To complement the drawbacks of gene wexpression system using viral promoters, the present inventors cloned promoter and 5' UTR of human EFl a gene. Particularly, the chromosomal DNA fragment encompassing promoter, exon 1, intron A and nucleotide sequences just before ATG codon of exon 2 region of EFl a gene, was amplified by PCR using human placental RNA as a template. The PCR product was replaced with HCMV enhancer/promoter region of pCDNA3.1 vector for construction of pEF. Thus, pEF vector contains EFl a promoter and entire 5'UTR (exon 1, intron A and partial exon 2) at upstream of the multi-cloning site. The gene expression of foreign gene inserted into the multi-cloning site is derived from spliced messenger RNA. 2) Gene expression level of pEF vector In order to compare the gene expression efficiency of pCN and pEF vectors, the vectors were were transfected to HeLa cell and CAT activities were measured 2 days after transfection. As a result, m transient expression system, the pCN vector showed 2 fold higher CAT activity than pEF vector. However, when CAT activities were compared using stably transfected cells selected for a long time, the CAT activity of cells transfected with pEF showed higher levels gene expression that of cells transfected with pCN . Namely, HCMV IE promoter drives transiently high- level gene expression in cell culture system, but drives low-level gene expression in stable system. However, in stable expression system, EFl a promoter derived from cellular gene works more efficiently than HCMV IE promoter derived from viral gene. Therefore, pEF vector is preferable for a long- time stable gene expression whereas pCN vector is preferable for transient gene expression. 3. Construction of chimeric plasmid pCEF 1) construction of pCEF vector To construct a novel expression vector with all advantages of both pCN and pEF, chimeric plasmid pCEF was constructed. Concretely, enhancer of HCMV IE gene was inserted at the upstream of promoter region of pEF and promoter and intron of EFl gene was maintained, allowed to drive high levels of gene expression both transiently and stably. First, the unnecessary intron sequences from +57 to +409 position in about 900 bp-length intron of the pEF vector was depleted, and generating pEFs. The enhancer sequence of HCMV IE gene was amplified by PCR, and then inserted at upstream of EFl a promoter of the depleted, pEFs vector, generating the chimeric vector, pCEF. 2) gene expression level of pCEF vector To compare the transcription efficiency of the chimeric vector with that of other known vectors, pCEF- CAT was constructed by inserting the CAT fragment into BamHI site of pCEF. pCN-CAT and pEF-CAT, were transfected to 293T cells, respectively and the CAT activities were measured 2 days after transfection. PCEF produced 5-fold, and 2-fold higher levels of CAT activity than pEF and pCN did, respectively. 4. Construction of pCK suitable for naked DNA gene therapy 1) construction of pCK In order to make pCN better fit in the context of naked DNA gene therapy, we have modified backbone of pCN, eventually constructing pCK. In pCK, the D- lactamase gene was replaced with the gene conferring the resistance to kanamycin because residual ampicillin in final DNA solution might cause allergic reactions to some patients undergoing gene therapy trials. Furthermore, all possible nucleotide sequences unnecessary for a vector to function as a gene delivery vehicle were removed from the plasmid in order to minimize the size of the plasmid to 3.7 kb, resulting in a relatively high copy number in E . coli . 2) Gene expression level of pCK pCK vector was expressed efficiently by E . coll and the safety was improved. As an embodiment of this vector, pCK-VEGF165 was constructed and the level of gene expression was measured in vivo/in vi tro . As shown in the result, the gene expression level derived from the pCK was 30-fold higher than that from control vector pCP which lacking 5' UTR, suggested that the said pCK-VEGF165 vector could be used for the treatment of ischemic disease. 5. Use of pCK, pEF, pCK and pCEF vectors as gene therapy agents In order to test the possibilities of using above pCN and pEF vectors as gene therapy agents, pCN-VEGF, pEF-VEGF and pCEF-VEGF vectors were constructed by inserting of VEGF gene into pCN, pEF and pCEF vectors, respectively. And then, the constructed vectors were transfected to mouse muscle cell lines C 2 C 12 (ATCC CRL- 1772), and the VEGF protein level was measured by ELISA. All of the above three vectors produced high levels of VEGF protein. Additionally, to investigate the protein expression level in vivo, the constructed vectors were injected into the anterior fibialis muscle of 2-week- old Balb/C male mouse, and the amount of VEGF protein produced was measured 2 days after injection. As a result, pCN-VEGF and pCEF-VEGF produced higher levels of VEGF activity than pCEF-VEGF in the injected muscle. These results suggested that pCN and pCEF vectors could drive high-level gene expression in vivo and in vi tro . As mentioned above, the pCK vector was produced in high copy number in E . col i and the safety improved. As an embodiment of this vector, pCK-VEGF165 was constructed and the level of gene expression was investigated m vivo/ in vi tro . In result, the expression level of the vector is more than 30 times as high as that of pCP vector without 5' UTR, and thus the said pCK-VEGF165 vector can be used for treatment of mchemic disease. As pre-clinical test for a new drug development, the time-course of protein production and the acute toxicity test were performed. The E . coli transformant by pCN/VEGF vector was designated to Λ Topl0-pCN/VEGF' and deposited to Korean Culture Center of Microorganisms on Nov 19, 1998 (Accession NO: KFCC-11064). The E . col i transformant by pEF/VEGF vector was designated to ToplO-pEF/VEGF' and deposited to Korean Culture Center of Microorganisms on Nov 19, 1998 (Accession NO: KFCC-11063). The E . coli transformant by pCK-VEGF165 vector was designated to ToplO-pCK/VEGF165' and deposited to Korean Culture Center of Microorganisms on December 27, 1999 (Accession NO: KCCM-10179). By all results, because of their abilities to drive high levels of gene expression, pCN, pEF, pCEF and pCK vectors can be applied for continuous expression of foreign gene, especially for naked DNA gene therapy m vivo . Specially, the use of backbone plasmid pCK is suitable for naked gene therapy because of the improved safety and the increased productivity of the vector. EXAMPLES Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples. However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention. Example 1: construction of pCN To construct pCN, the full length of IE enhancer/promoter (hereinafter referred to as λX P CMV ") of HCMV and its entire 5' untranslated region (5' UTR) was cloned by PCR. pEQ276 vector (Biegalke et al., Virology, 183:381-385(1995)) containing from the promoter to exon 5 of HCMV IE gene was used as a template and two synthetic oligonucleotides which were described by SEQ ID NO: 1 and NO: 2 were used as primers. The amplified 1.6kb DNA fragment corresponded to the nucleotide sequence containing enhancer/promoter, exon 1, intron A and upstream sequence of initiation codon of exon 2 (SEQ. ID NO: 3) . Nucleotide sequence from 1 to 599 corresponded to P CHV , sequence from 600 to 720 did to exon 1, sequence from 721 to 1547 did to intron A and sequence from 1548 to 1564 did to upstream sequence of initiation codon of exon 2. The PCR product was cloned into pZeroBlunt vector ( Invitrogen) to generate pZero-CMV. Then, the Mlul-Hindlll fragment containing P c .- of pCDNA3.1 vector ( Invitrogen) was replaced with the Mlul/Hindlll fragment of the resulting vector pZero-CMV, generating pCN vector (see FIG 1) . Therefore the backbone of pCN is identical to pCDNA3.1 containing multi-cloning site, BGH (bovine growth hormone) polyadenylation signal region (hereinafter referred to as "pA"), SV40 promoter (hereinafter referred to as "PSV40") and replication origin, neomycin antibiotic gene (hereinafter referred to as "NEO") and ColEl replication origin as well as P CMv - P CN differs from pcDNA3.1 in which entire 5'UTR of HCMV IE (exon 1, intron A and partial exon 2) in upstream of the multi- cloning site, thus the foreign gene inserted into the multi-cloning site was expressed from spliced messenger RNA. E . coli transformed by the said pCN vector was desingnated λ ToplO-pCN' and deposited in Korean Culture Center of Microorganisms on July 20, 1998 (Accession NO: KFCC-11045) . Example 2 : construction of pEF To construct pEF, the promoter region of human EFl a gene and its 5'UTR was cloned by PCR using a pair of primers which were described by SEQ ID NO: 4 and NO: 5. 1.2 kb-length DNA fragment of PCR product contains enhancer/promoter (hereinafter referred to as "P E -'), exon 1, intron A and upstream sequence of ATG codon of exon 2 derived from EFl a gene (SEQ ID NO: 6). The nucleotide sequence from 1 to 137 corresponded to P EF , sequence from 138 to 158 did to exon 1, sequence from 159 to 1104 did to intron A and sequence from 1105 to 1136 did to upstream sequence of ATG codon of exon 2. The PCR product was cloned into pZeroBlunt vector generating pZero-EFl a . The Mlul/Nhel region of pCDNA3.1 vector was replaced with Mlu/Nhel fragment prepared from the pZero-EFl a , generating pEF vector (see FIG 2) . Because the backbone of pEF is identical to pCDNA3.1, pEF contains multi-clonmg site, BGH pA, P 40 and replication origin, NEO and ColEl replication origin. In addition, it contains P r „ and its 5'UTR of HCMV IE (exon 1, intron A and partial exon 2) at upstream of the multi-clonmg site, thus the foreign gene inserted into the multi-clonmg site was expressed from spliced messenger RNA. Example 3: construction of pCEF It was observed that the pCN produced high levels of gene expression n transient transfection system, while the pEF produced high levels of gene expression in stable transfection system. So the inventors of this invention constructed a chimeric vector to take both advantages of the two vector system. Namely, the chimeric vetor was constructed by inserting the enhancer region of HCMV gene into the 5' end of P thus allowed to maintain the rest of the structure. The enhancer sequence of HCMV IE gene was cloned by PCR amplification of pEQ276 using a pair of primers described by SEQ ID NO: 7 and NO: 8. The original pEF vector contains about 900 bp- length intron. To reduce the size of the intron, the nucleotide sequence from +57 to +409 position was removed by internal deletion using SacII restriction enzyme, generating pEFs . Bglll-SnaBI HCMV enhancer fragment was inserted into Nrul-Bglll site of pEFs, generating pCEF. Example 4 : construction of pCK In order to make vector better fit in the context of naked DNA gene therapy, we have modified backbone of pCN, eventually constructing pCK. In pCK, the C- lactamase gene was replaced with the gene conferring the resistance to kanamycin because residual ampicillin in final DNA solution might cause allergic reactions to some patients undergoing gene therapy trials . Furthermore, all possible nucleotide sequences unnecessary for a vector to function as a gene delivery vehicle were removed from the plasmid in order to minimize the size of the plasmid, resulting m a relatively high copy number in E . coli . The nucleotide sequences encompassing promoter region and its 5' UTR, and BGHpA region of pCN vector was amplified by PCR using a pair of primers described by SEQ ID NO: 9 and NO: 10. The DNA fragment was cloned into pCR2.1 vector (Invitrogen) , generating pCR2.1CMVpA. The resulting vector was then treated with restriction enzyme and Mlul/Sall, the fragment containing PCRed was purified. Then, the fragment containing kanamycin resistance gene and ColEI replication origin was isolated from pZero2.1 vector ( Invitrogen) using Apol and Afllll, religated with Mlul/Sall fragment from pCR2.1CMVpA, constructing pCK vectorfsee FIG 4). Example 5 : construction of pCN-VEGF cDNA encoding human VEGF121 gene was cloned from total RNA prepared from human placenta by RT- PCR (reverse transcription PCR). PCR primers were described by SEQ ID NO: 11 (sense primer) and NO: 12 (antisense primer) . The RT-PCR product was cloned into pCR2.1 vector (Invitrogen) and £col.I fragment of the resulting vector was inserted into EcoRI site of pCN vector, generating pCN-VEGF vectorfsee FIG 5). Example 6: construction of pEF-VEGF All the procedures were conducted according to Example 5, except that pCN vector was replaced with pEF \ector Example 7 : construction of pCEF-VEGF All the procedures were conducted according to Example 5, except that p CN vector was replaced with pCEF vector. Example 8 : construction of pCK-VEGF cDNA encoding VEGF165 was cloned from total RNA prepared from human vascular smooth muscle cells by RT- PCR. PCR primers were described by SEQ ID NO: 13 and NO: 14. The amplified cDNA was initially cloned into the pCR2.1 vector ( Invitrogen) , and its nucleotide sequence was continued by sequencing. The Hindl ll /Xbal fragment containing VEGF165 from pCR2.1-VEGF165 was inserted into Hindlll/Xbal site of pCK vector, generating pCK-VEGF165 (see FIG 6) . E . col i transformed by pCK-VEGF165 was designated λ ToplO-pCK/VEGF165' and deposited to Korean Culture Center of Microorganisms on December 27, 1999 (Accession NO: KCCM-10179) . Example 9: construction of pCP and pCP-VEGF As a control plasmid, pCP whose backbone is identical to that of pCK except that it lacks the untranslated leader sequences of the major IE region of HCMV was constructed. The pCP was constructed by inserting the Ndel / Hindl ϊ l fragment from pCDNA3.1 into Ndel / Hindll l site of pCK(see FIG 7) . And then, pCP-VEGF165 vector was constructed by inserting the Hindlll/Xbal fragment of pCK-VEGF165 containing VEGF165 gene into Hir-dlll/Xfoal site of pCP. Example 10: Effect of HCMV IE 5'UTR region on the levels of gene expression 1) construction of pCDNA3.1-CAT, pCIneo-CAT and pCN-CAT To compare the levels of gene expression from pCN with other commercially available vectors, we chose pCDNA3.1 (Invitrogen) and pCIneo ( Promega) . pCDNA3.1 contains P CM alone, whereas pCIneo contains heterologous synthetic intron. pCDNA3.1-CAT, pCN-CAT and pCIneo-CAT were constructed through the insertion of CAT reporter gene into BamHl site of each plasmid, respectively (see FIG 8) . 2) comparison the level of gene expression The pCN-CAT, pCDNA3.1-CAT and pCIneo-CAT vector, were transfected to 293T cells ( DuBridge et al . , Mol . Cel l . Biol . , 7:379-387, 1987) . 2 days after transfection, protein extracts were prepared to measure the level of gene expression. As a result, as shown m table 1, the CAT activity from pCN-CAT containing 5' UTR was 60 fold higher than those from control vectors. These results suggest that the 5' UTR sequences attribute to increase the level of gene expression. Table 1 Effect of HCMV IE 5' UTR insertion on gene expression efficiency Example 11: Effect of pCN vector on virus packaging In order to investigate the effect of the above constructed pCN vector on the gene expression efficiency and on retroviral packaging, retroviral vectors, gag-pol vector and env vector, were constructed, using the pCN vector as elementary backbone. To distinguish the marker from the inherent neomycm gene of retroviral vectors, the marker gene inserted into the above packaging vector was puromycm antibiotic gene for gag-pol vector and hygromycm antibiotic gene for env vector, respectively. 1) pCP-gag/pol vector construction The pCP-gag/pol vector, which contained puromycm gene as marker for eukaryote and enhancer/promoter and 5' UTR sequence of HCMV IE gene as regulator, was constructed: First, neo gene was deleted from the pCI-neo vector (Promega) and then pCI-puro vector was constructed through insertion of puromycm gene fragment separated from pCII-puro vector into the resulting vector (see FIG 9a) . After the above pCI-puro vector was deleted P αr fragment through treatment of Bglll and Nhel, pCP vector was constructed through insertion of Mlul -HindiII fragment containing P αr and 5' UTR sequence separated from the pCN vector prepared m example 1 into the pCI-puro vector (see FIG 9a) . On the other hand, pCIII-gag/pol vector was constructed through insertion of the gag-pol fragment into the pCII vector ( Invitrogen) , wherem the gag-pol fragment originated from MLV (murine leukemia virus) was amplified by PCR, using the conventional gag-pol expression vector, pHITδO (Cannon et al . , J. Virol . , 70:8234-8240, 1996), as template and the synthetic polynucleotides described by SEQ ID NO: 15 and NO: 16 as primers . And then, the gag-pol fragment of the above pCII- gag/pol vector was inserted into the Mlul-Hindlll site of the above pCP vector, constructing the gag-pol expression vector, pCP-gag/pol vector. 2) pCH-env vector construction The pCH-env vector, which contained hygromycm gene as marker for eukaryote and enhancer/promoter and 5' UTR sequence of HCMV IE gene as regulator, was constructed: First, neo gene was deleted from the pCI-neo vector (Promega) and then pCI-hygro vector was constructed through insertion of DNA fragment containing hygromycm gene and MMTV (mousse mammary tumor virus) LTR(long terminal repeats) separated from pCII-MMTVhyg vector into the resulting vector (see FIG 5a) . After the above pCI-hygro vector was deleted P cm fragment through treatment of Bglll and Nhel, pCH vector was constructed through insertion of Mlul - Hmdl l l fragment containing P cκ - and 5' UTR sequence separated from the pCN vector prepared m example 1 into the pCI-hygro vector (see FIG 10a) . On the other hand, pCH-env vector was constructed through insertion of the env fragment into the pCII vector ( Invitrogen) , wherem the env fragment originated from MLV (murine leukemia virus) was amplified by PCR, using the conventional env expression vector, pHIT456 (Cannon et al . , J. Virol . , 70:8234-8240, 1996), as template and the synthetic polynucleotides described by SEQ ID NO: 17 and NO: 18 as primers. And then, the env fragment of the above pCII-env vector was inserted into the Ml ul-Notl site of the above pCH vector, constructing the env expression vector, pCH-env vector(see FIG 10b). 3) Examination of packaging efficiency To compare the packaging efficiency of the pCP- gag/pol vector and pCH-env vector prepared above with that of conventional packaging vectors, after retroviral MFC-CAT vector (Kim et al . , J. Virol., 72:994-1004,1998), together with pCP-gag/pol and pCH- env vectors, were transfected to 293T cells and the transfected cells were cultured for 48 hours, cell-free viral supernatants were obtained by filtrating the cultured medium with 0.45-j-.m filter. And then, after the virus were transfected to NIH3T3 cells (ATCC CRL 1658) and the transfected cells were cultured for 48 hours, the efficiency of the retroviral packaging was determined by measurement of CAT activity of the cytosolic protein extract. As a result, as shown m table 2, it was found that the packaging efficiency of the pCP-gag/pol and pCH-env vector of this invention was increased by about 20 % in comparison with that of the conventional vectors. This suggests that further insertion of the 5' UTR sequence besides the enhancer/promoter sequence help the recombinant vectors to be useful as multipurpose eukaryotic gene expression vectors. Table 2 Effect of HCMV IE 5'UTR on packaging efficiency Example 11: Comparison levels the gene expression from pCN f pEF and pCEF vector in cell-culture system. pEF-CAT vector was constructed by inserting CAT fragment into Hindlll/Xjal site of pEF vector (see FIG 12) . pCN-CAT and pEF-CAT were transfected to HeLa cells. 2 days later, CAT activities were measured to compare the levels of gene expression. The gene experssion level of pCMV was set to 1 and those of others were normalized to it. As show in Table 3, in transient transfection system, where gene expression was derived from episomal plasmid not from chromosome, the P CMV drived higher levels of gene expression than pEF did. In addition, to compare the gene expression level from pCEF with others, pCEF-CAT vector was constructed by insertion of CAT fragment into BamHl site of pCEF. Plasmids pCEF-CAT, pCN-CAT and pEF-CAT were transfected to 293T cells, and CAT activities were measured 48 hours after transfection Table 3 As shown in table 3, the CAT activity of the chimeric vector was about 10 fold, and 2-fold higher than that of pEF-CAT, and pCN-CAT, respectively. Example 13: Time course of gene expression continuous expression system To examine how long and how much the CAT gene could be expressed in continuous culture system, the stable transfected cell lines were generated. Hela cells were transected with pCN-CAT or pEF-CAT and selected with G418. After G418 resistant cells were obtained, CAT activities from each cell line were compared. As shown in Fig.14 the CAT activity of transfected cells with pEF-CAT was close to that of trasfected cells with pCN-CAT. This result suggested that once integrated into the chromosome, the activity of P c , r . decreased whereas the activity of P EF was maintained . To confirm the above results, the CAT activities from cell lines stably transfected with pCN-CAT or pEF- CAT were measured for 6 weeks as a result, at the beginning, the CAT activity from HCMV promoter was 3 folds higher than that from EFlα promoter. However, 2 weeks later, the CAT activity from HCMV promoter lowered than that from EFlα promoter (see FIG 15) . These results confirmed that the level of gene expression derived from P CMV decreased after integrated into the chromosome. Example 14 : Comparison the levels of gene expression in subclones . The activities from cell population represent the mean value of the heterogeneous members. However, to use them for industrial purpose, subclones should be characterized. Thus, to examine properties of each subclone, ring cloning method was performed to isolate subclone from population. 25 subclones were isolated from cells transfected with pCN-CAT, and 13 subclones were obtained from cells transfected with pEF-CAT. The results showed that 3 of 25 subclones with PCMV produced significantly high levels of gene expression, whereas most of the remains did not produce CAT protein(see FIG 16) . To summarize, most clones derived from stably transfected cells with P CH seemed to be inactive . In contrast, 7 of 13 subclones with P EF produced significantly high levels of gene expression. These results suggested that in continuous culture system promoter derived from cellular gene, like EFlα could drive more stable and efficient gene expression than viral promoter P CMV could. Example 15: expression level of VEGF 1) VEGF expression in vivo To examine the level of VEGF expression in vivo, the plasmid was injected into anterior tibialis of 2- week-old BALV/C mouse. Two days after injection ELISA was performed using whole protein extracted from the injected muscle. As shown in Fig 17, the level of VEGF expressed in the muscle was significantly high. 2) Comparison the level of VEGF expression from CDNA3.1-VEGF165, pCN-VEGF165, pEF-VEGFl65 and pCEF- VEGF165 in vivo . To compare the level of gene expression in vivo, lOOμg of plasmids pCDNA3.1-VEGF165, pCN-VEGF165, pEF- VEGF165 and pCEF-VEGF165, were injected into anterior tibialis of 4-week-old BALV/C mouse. 2days later, ELISA was performed with protein extracts from the injected muscle. The results showed that the VEGF expression 50 lefel from pCEF was 9-fold, and 3-fold higher than that from pEF, and pCN, respectively (Fig .17 ) . Example 16: Comparison the level of gene expression from pCK and pCP in vivo 1) Construction of pCK-CAT and pCP-CAT To compare the levels of gene expression from pCK with that from pCP which lacks 5 UTR of HCMV IE gene, pCK-CAT and pCP-CAT were constructed by insertion of CAT reporter gene into Hindlll/Xbal site of pCK and pCP vector respectively (see FIG 18) . 2) Comparison the level of gene expression from pCK and pCP in vitro pCK-CAT and pCP-CAT were transfected to C2C12 cells, and the level of CAT activity was measured 2days later. As shown in the result, CAT activity from pCK vector was 30 fold higher than that from pCP(Fig.l9) . 3) Comparison the level of VEGF expression from pCK-VEGF165 and pCP-VEGF165 pCK-VEGF and pCP-VEGF were used to transfect C2C12 cells (ATCC CRL-1772) and the levels of VEGF expression were measured 2days later. As a result, it was noted that the expression level from pCK-VEGF was 30-fold higher than that from pCP(see FIG 20) . Example 17: Comparison the levels of gene expression 1) Comparison of pCP-CAT and pCK-CAT m vivo 100 μg of pCK-CAT and pCP-CAT were injected into anterior tibialis of 2-4-week-old Balb/C male mouse. 48 hrs later, the CAT activities were measured. As shown in Fιg21, gene expression level from pCK-CAT was 30 fold higher than that form pCP-CAT(see FIG 21) 2) Comparison of pCP-VEGF and pCK-VEGF in vivo In order to investigate the feasibility of using pCK-VEGF165 vector for naked DNA gene therapy, pCK- VEGF165 and pCP-VEGF165 were injected into anterior tibialis of 2-4-week-old Balb/C male mouse and then ELISA(R&D systems: n=41) was performed using the protein extracts from injected mouse muscle. Particulary, the injection was performed using insulin syringe with 1 mg/ml of DNA dissolved in PBS, wherem DNA was isolated using Endotoxm-free column (Qiagen, Inc.) . As shown m the results, pCK-VEGF produced higher levels of gene expression than pCP-VEGF165 in vitro. These results suggests that pCK vector can be used naked DNA gene therapy (see FIG 22) . Example 18: Time-course of gene expression 1) Time course of CAT production level in vivo In order to obtain the pharmaceutical kinetics of CAT production in vivo, 100 μg of pCK-CAT vector was injected into anterior tibialis of 2-4-week-old Balb/C male mouse, and the CAT activity was measured for 2 weeks using 9-15 head of mouse. As show in the result, The CAT expression from pCK-CAT vector continued for 2 weeks after injection (see FIG 23) . 2) Time-course of VEGF165 expression in vivo To know kinetics of VEGF expression in vivo, 100 μg of pCK-VEGF165 vector was injected into anterior tibialis of 2-4-week-old Balb/C male mouse and the changes of VEGF165 level were measured for 2 weeks using 12 head of mouse. As shown in Fig 24, the VEGF165 gene expression from pCK-VEGF vector was continued for 2 weeks after injection (see FIG 24). Example 19: Dose-dependency of gene expression 1) Dose-dependency of CAT expression. To test the effects of plasmid concentration on the expression level, 2-4-week-old Balb/C male mouse were injected with increasing doses of pCK-CAT, proteins extracted from the injected site 2days later and analyzed. The results showed that the amount of injected pCK-CAT was closely related with level of gene expression (see FIG 25) . 2) Dose-dependency of VEGF expression in vivo To test the effects of plasmid concentrations on the expression level, 2-4-week-old Balb/C male mouse were injected with increasing doses of pCK-VEGF. 2 days after injection, the mouse was killed and whole protein of the injected region was extracted to be analyzed by ELISA (n=8-10) . The results, it was confirmed above observation that the amount of injected pCK-VEGF was closely related with the level of gene expression ( see FIG 25). Example 20: Acute toxicity test by parenteral administration to rat mouse Acute toxicity test was performed using 4-week-old Balb/C SPF mouse, mice were devided by 5 groups and each group of mice were injected with increasing doses of pCK-VEGF165 at the interval of 0.5 upto maximum concentration of 50mg/kg. Plasmids were dissolved in isotonic water, and the injected volume was 200μl. 4-week-old SD SPF, rats were also divided by 5 groups, and each group of rats were injected with increasing doses of pCK-VEGF165 at the interval of 0.5 upto maximum concentration of 200mg/kg. Plasmids were dissolved in isotonic water, and the injected volume was 500μl. JD Each group was composed of 5 head of mice, and individuals with standard weight were distributed evenly. The DNA solution was administrated using insulin injector into anterior tibialis of the mouse and rat. An equal amount of PBS was administrated to control group, a week after the administration, death, clinical diagnosis and change of weight of the animals are observed. Then, the animals were autopsied to observe the possible disorders of internal organs. In every animals tested, any disorder thought to induced by administration of plasmids expressing VEGF was not found. Consequently, the minimal lethal dose of the pCK-VEGF was regarded as 50 mg/kg for mouse and 200 mg/kg for rat. INDUSTRIAL APPLICABILITY As described above, the present invention provides efficient eukaryotic gene expression vectors capable of driving high levels of gene expression in various eukaryotes. The specific properties of vectors of this invention as follows: 1. To construct the vectors using HCMV IE and human EFl a regulatory region, promoter as well as entire 5'UTR(exon 1, intron A, partial exon 2) are used to drive high levels of gene expression m various eukaryotic cells. 2. The vectors with promoter and 5'UTR region of HCMV IE gene can drive strong gene expression m transiently transfected animal cells. 3. The vectors with promoter and 5'UTR region of EFlα gene can drive high and stable gene expression animal cells so that high-qualifled cell lines can be established . 4. Since the vectors with promoter and 5'UTR region of HCMV IE gene can drive high levels of gene expression m vivo, they can be utilized for naked DNA gene therapy . 5. The chimeric vector comprising HCMV IE enhancer, EFlα promoter and EFl 5'UTR drives higher levels of gene expression than the original vectors . Those skilled m the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims .

Claims: What is Claimed is 1. Eukaryotic expression vectors which contains multi- clon g site, poly A signal for transcriptional termination, selectable marker gene, replication on gene of E . coli , and exogenous regulatory elements which provides strong transcriptional activity. 2. Eukaryotic gene expression vectors according to claim 1, which is pCEF vector containing promoter and entire 5' untranslated region of human EFl gene and enhancer of HCMV IE gene at upstream of the EFl promoter to drive strong transcriptional activity . 3. Eukaryotic gene expression vector according to claim 1, which is pCN vector whose exogenous regulatory elements comprise promoter/enhancer, exon 1, mtron A and nucleotide sequences ust before ATG initiation codon of exon 2 derived from HCMV IE gene. 4. Eukaryotic gene expression vector according to claim 1, which is pEF vector whose exogenous regulatory elements comprise promoter/enhancer, exon 1, mtron A and base sequences just before ATG initiation codon of exon 2 derived from human EFl a gene . 5. Eukaryotic gene expression vector according to claim 2, claim 3 or claim 4, which contains human VEGF gene multi-clonmg site. 6. A E . col i ToplO-pCEF transformed with the pCEF vector of claim 2 (Accession NO: KFCC-10180). 7. A E . col i Top-pCN/VEGF transformed with the pCN/VEGF vector of claim 5 (Accession NO: KFCC-11064). 8. A E . col i ToplO-pEF/VEGF transformed with the pEF/VEGF vector of claim 2 (Accession NO: KFCC- 11063) . 9. Eukaryotic gene expression vector according to claim 2, claim 3 or claim 4, wherem unnecessary genes are deleted to minimize the vector size and the ampicilin resistance gene is replaced with kanamycme resistance gene. 10. Eukaryotic gene expression vector of claim 9, which is pCK vector whose exogenous regulatory elements contains promoter/enhancer and 5' untranslated region derived from HCMV IE gene. 11. Eukaryotic gene expression vector according to claim 10, which is pCK/VEGF vector containing human VEGF gene in multi-cloning site. 12. A E . coli ToplO-pCK/VEGF165 transformed with the pCK/VEGF165vector of claim 11 (Accession No: KFCC- 11121) . 13. Gene therapy agent containing the pCK vector of claim 10. 14. Gene therapy agent of claim 13, wherein the vectors are pCK/VEGF121 or pCK/VEGF165 that VEGF121 or VEGF165 are inserted into pCK, respectively.

Inventors: KIM DUK-KYUNG, KIM SUNYOUNG, LEE YOUNG JOO, YU SEUNG SHIN, KIM, DUK-KYUNG, KIM, SUNYOUNG, LEE, YOUNG, JOO, YU, SEUNG, SHIN
Applicants: KIM DUK KYUNG, KIM SUNYOUNG, LEE YOUNG JOO, VIROMED LIMITED, YU SEUNG SHIN, KIM, DUK-KYUNG, KIM, SUNYOUNG, LEE, YOUNG, JOO, YU, SEUNG, SHIN
Application year: 1999
Main classification: C12N15
IPC codes: A61K38, A61K48, A61P9, C12N1, C12N15